Ahmed Y. Abdelbadee Hefnawy, Obstetrics and Gynecology Specialist Trainee at Nottingham University Hospitals NHS Trust and Obstetrics and Gynecology Lecturer at Assiut University, shared a post on LinkedIn.
“Insights from ESGO 2026: The Evolving Role of Radiotherapy in Oligometastatic Recurrent Ovarian Cancer
In a compelling summary at ESGO 2026, Dr. Viola Heinzelmann-Schwarz (Basel) highlighted the critical decision-making nodes for treating recurrent ovarian cancer oligometastatic disease. As we move toward more personalized care, the integration of radiotherapy (RT) is becoming a vital alternative to surgery.
Key Takeaways:
- Defining the Disease: There is a pressing need for standardized definitions of “oligometastatic disease” to streamline treatment protocols.
- Clinical Context is King: Recurrence must be differentiated based on whether it occurred during maintenance therapy and if platinum-based options are still viable.
- RT as a Definitive Tool: For patients who are not candidates for surgery, metastasis-directed definitive radiotherapy using IMRT/SBRT should be considered.
- Palliative Support: Short-course RT remains an effective tool to alleviate symptoms and maintain quality of life.
- The Evidence Gap: Dr. Heinzelmann-Schwarz emphasized an urgent need for international trials to gain more data regarding the interplay between secondary cytoreduction and RT.
The message is clear: precision, differentiation, and more robust clinical data are the keys to advancing the standard of care.”
Other articles about ESGO on OncoDaily.
